What's New From the USPSTF

Screening for Cervical Cancer


This series of fact sheets is based on the work of the U.S. Preventive Services Task Force (USPSTF). The USPSTF systematically reviews the evidence of effectiveness of a wide range of clinical preventive services—including screening, counseling, and chemoprevention (the use of medication to prevent diseases)—to develop recommendations for preventive care in the primary care setting.

This fact sheet presents highlights of USPSTF recommendations on this topic and should not be used to make treatment or policy decisions.

Select for PDF File (75.5 KB). PDF Help.


What Screening Is Recommended by the USPSTF?

The Task Force concludes that screening should begin within 3 years of the start of sexual activity or age 21, whichever comes first, and should be done at least every 3 years. The risk for cervical cancer and the yield of screening decline through middle age.

For women older than 65 who have had normal Pap smears, the benefits of continued screening may not outweigh the potential harms, such as false-positive test results and invasive procedures. The Task Force also concludes that the yield of detecting vaginal neoplasms is too low to justify continuing screening after a total hysterectomy.

Most cases of cervical cancer occur in women who are not screened adequately. Clinicians, hospitals, and health plans should develop systems to identify and screen women, including older women, who have had no screening or who have been screened inadequately in the past.


Most cases of cervical cancer occur in women who are not screened adequately.


Why Aren't Annual Pap Tests or Newer Technologies Recommended?

The USPSTF found no direct evidence that annual screening is more effective than less frequent screening in preventing cases of cervical cancer or death from cervical cancer. Cervical cancer usually progresses from precancerous lesions to invasive cancer over many years. Unless women are at increased risk for cervical cancer, screening less frequently is likely to be effective while reducing the number of false-positive results.

The available data are insufficient to determine whether newer, more expensive forms of Pap tests are better than conventional Pap tests. Although some data suggest new tests like ThinPrep® may detect more high-grade lesions, they may also increase false-positive results. HPV tests are not yet approved for use as primary screening tests for cervical cancer but research is underway to determine whether HPV tests can identify women who need more or less frequent screening with Pap tests.

How Do These Recommendations Differ from Previous Task Force Recommendations?

These recommendations reinforce earlier recommendations that sexually active women get regular Pap testing at least every 3 years. The revised recommendations, however, raise the age at which routine screening should begin, as a result of data suggesting that the risk for cervical cancer in adolescents is low and the risk for false-positive results is high. The recommendation against continuing routine screening in women after age 65, or after a total hysterectomy, are stronger than in 1996, reflecting new data on the low yield and potential harms of such screening.

For more information on screening for cervical cancer, contact the following organizations:

healthfinder™
http://www.healthfinder.gov

National Cancer Institute
National Institutes of Health
http://www.nci.nih.gov

USPSTF Members

Members of the USPSTF represent the fields of family medicine, gerontology, obstetrics-gynecology, pediatrics, nursing, prevention research, and psychology. Members of the USPSTF are:

Alfred O. Berg, M.D., M.P.H., Chair  C. Tracy Orleans, Ph.D. 
Janet D. Allan, Ph.D., R.N., C.S., Vice-chair  Jeffrey F. Peipert, M.D., M.P.H.* 
Paul S. Frame, M.D.  Nola J. Pender, Ph.D., R.N.* 
Charles J. Homer, M.D., M.P.H.*  Albert L. Siu, M.D., M.S.P.H. 
Mark S. Johnson, M.D., M.P.H.  Steven M. Teutsch, M.D., M.P.H. 
Jonathan D. Klein, M.D., M.P.H.  Carolyn Westhoff, M.D., M.Sc. 
Tracy A. Lieu, M.D., M.P.H.*  Steven H. Woolf, M.D., M.P.H. 

*Members of the USPSTF at the time the recommendation on cervical cancer screening was finalized.

AHRQ Publication No. APPIP03-0004
Current as of January 2003


Internet Citation:

Screening for Cervical Cancer. What's New from the USPSTF? AHRQ Publication No. APPIP03-0004, January 2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanwh.htm


U.S. Preventive Services Task Force (USPSTF)
Clinical Information
AHRQ Home Page